Dr. Licheng Wang, Shanghai Tongji Hospital, China
Dr. Licheng Wang (born October 16, 1992) is a urologist and research scientist at Shanghai Tongji Hospital 🎓. He holds a doctorate in urology and specializes in prostate cancer research, focusing on DNA damage repair, PSMA-targeted therapies, and drug resistance using single-cell and multi-omics analysis 🔬🧬. As a first or corresponding author, he has published in top-tier journals like Int J Biol Macromol, Current Oncology Reports, and Frontiers in Immunology 📚. Dr. Wang presented his work on SUMOylation and telomere biology at the 2021 Cold Spring Harbor meeting 🎤, emphasizing genomic stability in cancer
Publication Profile
Scopus
Academic Background
Dr. Licheng Wang (born October 16, 1992) is a dedicated urologist and researcher at Shanghai Tongji Hospital. 🎓 He holds a doctorate in Urology and specializes in prostate cancer research, focusing on 🔬 DNA damage repair mechanisms, PSMA-targeted therapies, and single-cell multi-omics of drug resistance. 📚 Dr. Wang has published several high-impact Q1 papers as first and corresponding author and has presented at leading conferences like Cold Spring Harbor. 🧬 His work contributes significantly to understanding and overcoming treatment resistance in castration-resistant prostate cancer (CRPC).
Academic Engagement
Dr. Licheng Wang is an accomplished urologist and cancer researcher at Shanghai Tongji Hospital. 🎓 Holding a doctorate in Urology, his work delves into 🔬 prostate cancer mechanisms, especially DNA repair, drug resistance, and PSMA-targeted therapies. 🧬 He actively engages in academic discourse, presenting cutting-edge findings at top-tier events, including a notable talk at the 2021 Cold Spring Harbor conference on SUMOylation and telomere biology—key to understanding genomic stability. 📚 With several Q1 publications as first or corresponding author, Dr. Wang is shaping future cancer treatments.
Research focus
Dr. Licheng Wang’s research focus lies in advanced prostate cancer biology and therapeutic innovation. His work primarily targets 🔁 drug resistance mechanisms, particularly in castration-resistant prostate cancer (CRPC) through metabolic and lncRNA pathways. 🧬 He explores the role of immune microenvironment and immune-related subtypes, providing insights into personalized cancer treatment. 🧠 Using cutting-edge imaging like PSMA-PET/CT, his research aids in accurate diagnosis and therapy redirection. 🧫 By combining molecular biology, multi-omics, and translational oncology, Dr. Wang contributes significantly to cancer prognosis, resistance profiling, and targeted therapies—making his research impactful in cancer genomics and clinical urology
Conclusion
Dr. Licheng Wang’s strong academic profile, impactful research publications, leadership roles in authorship, and active international engagement, he is an excellent candidate for the Best Researcher Award in Urology or Medical Research. His work is both innovative and clinically relevant, contributing meaningfully to the future of prostate cancer management.
Publication Top Notes
-
📄 2024 – Glycolysis-related lncRNA SNHG3/miR-139-5p/PKM2 axis promotes CRPC development and enzalutamide resistance – Co-corresponding Author, Int J Biol Macromol, Cited by: [Awaiting citations, newly published] 🔬
-
📄 2025 – The Evolving Role of PSMA-PET/CT in Prostate Cancer Management – First Author, Current Oncology Reports, Cited by: [Forthcoming, early release] 🧠
-
📄 2022 – Immune microenvironment infiltration and immune-related subtypes in prostate cancer – Corresponding Author, Front Immunol, Cited by: 45+ 🧬